SG11201909726YA - METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF - Google Patents

METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF

Info

Publication number
SG11201909726YA
SG11201909726YA SG11201909726YA SG11201909726YA SG 11201909726Y A SG11201909726Y A SG 11201909726YA SG 11201909726Y A SG11201909726Y A SG 11201909726YA SG 11201909726Y A SG11201909726Y A SG 11201909726YA
Authority
SG
Singapore
Prior art keywords
international
acetaminophen
composition
nsaids
optionally
Prior art date
Application number
Other languages
English (en)
Inventor
Thomas Jacobsen
Original Assignee
Hyloris Dev Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58645031&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201909726Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hyloris Dev Sa filed Critical Hyloris Dev Sa
Publication of SG11201909726YA publication Critical patent/SG11201909726YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11201909726Y 2017-04-20 2018-04-20 METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF SG11201909726YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2017/059440 WO2018192664A1 (en) 2017-04-20 2017-04-20 METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF
PCT/EP2018/060205 WO2018193099A1 (en) 2017-04-20 2018-04-20 METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF

Publications (1)

Publication Number Publication Date
SG11201909726YA true SG11201909726YA (en) 2019-11-28

Family

ID=58645031

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909726Y SG11201909726YA (en) 2017-04-20 2018-04-20 METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF

Country Status (20)

Country Link
US (1) US11413241B2 (zh)
EP (1) EP3612157A1 (zh)
JP (1) JP6944590B2 (zh)
KR (2) KR20230160413A (zh)
CN (1) CN110719773A (zh)
AR (1) AR111484A1 (zh)
AU (1) AU2018255376B2 (zh)
CA (1) CA3060325A1 (zh)
CL (1) CL2019002985A1 (zh)
CO (1) CO2019011569A2 (zh)
EC (1) ECSP19075614A (zh)
IL (1) IL270035B2 (zh)
MX (1) MX2019012508A (zh)
PE (1) PE20191793A1 (zh)
PH (1) PH12019502385A1 (zh)
RU (1) RU2019137019A (zh)
SA (1) SA519410340B1 (zh)
SG (1) SG11201909726YA (zh)
TW (1) TW201841632A (zh)
WO (2) WO2018192664A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115040475A (zh) * 2022-06-23 2022-09-13 杭州浙中医药科技有限公司 一种n-乙酰半胱氨酸口服溶液

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751875B1 (fr) 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
FR2809619B1 (fr) * 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
US20060100578A1 (en) 2004-09-13 2006-05-11 Tandem Medical, Inc. Medication delivery apparatus and methods for intravenous infusions
US20110124730A1 (en) 2008-01-03 2011-05-26 Wockhardt Research Centre Oral pharmaceutical suspension comprising paracetamol and ibuprofen
BRPI0914086A2 (pt) 2008-10-14 2020-01-21 Aft Pharmaceuticals Ltd uso de paracetamol e ibuprofeno na preparação de um medicamento para o tratamento de osteoartrite moderada ou severa ou artrite reumatoide moderada ou severa e método de tratamento de osteoartrite moderada ou severa ou artrite reumatoide moderada ou severa
EP2243477A1 (de) 2009-04-22 2010-10-27 Fresenius Kabi Deutschland GmbH Paracetamol zur parenteralen Verabreichung
US8404748B2 (en) 2009-08-13 2013-03-26 Neogen N.V. Storage-stable formulation of paracetamol in aqueous solution
PL2389923T3 (pl) 2010-05-19 2013-06-28 Uni Pharma Kleon Tsetis Pharmaceutical Laboratories S A Trwały, gotowy do użycia iniekcyjny preparat paracetamolu
PL2635269T3 (pl) 2010-11-04 2019-11-29 Aft Pharmaceuticals Ltd Kompozycja złożona
US9205037B2 (en) 2011-07-20 2015-12-08 Church & Dwight Co., Inc. Single phase depilatory composition
ES2414557B1 (es) * 2012-01-16 2014-06-10 Novocat Farma, S.A. Composición acuosa de paracetamol para inyección
BE1020614A5 (nl) 2012-01-27 2014-01-07 Hubert De Backer Nv Injectiespuit.
CN106890137B (zh) 2012-03-16 2020-09-25 坎伯兰医药品股份有限公司 可注射布洛芬制剂
US9072661B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
WO2016008546A1 (en) 2014-07-18 2016-01-21 Everbright Pharmaceuticals S.A.R.L. Aqueous formulation comprising paracetamol and ibuprofen

Also Published As

Publication number Publication date
JP2020522564A (ja) 2020-07-30
AR111484A1 (es) 2019-07-17
PH12019502385A1 (en) 2020-09-14
CN110719773A (zh) 2020-01-21
WO2018192664A1 (en) 2018-10-25
TW201841632A (zh) 2018-12-01
AU2018255376A1 (en) 2019-11-07
EP3612157A1 (en) 2020-02-26
RU2019137019A (ru) 2021-05-20
RU2019137019A3 (zh) 2021-07-05
SA519410340B1 (ar) 2022-03-13
KR20230160413A (ko) 2023-11-23
IL270035B1 (en) 2023-01-01
JP6944590B2 (ja) 2021-10-06
IL270035A (zh) 2019-12-31
WO2018193099A1 (en) 2018-10-25
CL2019002985A1 (es) 2020-01-31
CO2019011569A2 (es) 2021-03-08
PE20191793A1 (es) 2019-12-24
AU2018255376B2 (en) 2023-07-06
MX2019012508A (es) 2020-02-05
ECSP19075614A (es) 2019-11-30
US20210338578A1 (en) 2021-11-04
US11413241B2 (en) 2022-08-16
CA3060325A1 (en) 2018-10-25
KR20190137859A (ko) 2019-12-11
IL270035B2 (en) 2023-05-01
KR102625301B1 (ko) 2024-01-15

Similar Documents

Publication Publication Date Title
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201807437XA (en) Antibodies specific to human poliovirus receptor (pvr)
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201903697WA (en) Liver organoid compositions and methods of making and using same
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201901371XA (en) Methods for the detection of genomic copy changes in dna samples
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201809252YA (en) Methods for determining dpp3 and therapeutic methods
SG11201806267QA (en) Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201808525UA (en) Anti-complement factor bb antibodies and uses thereof
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201407801VA (en) Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations
SG11201902567WA (en) Expec glycoconjugate vaccine formulations
SG11201407536UA (en) Topical pharmaceutical compositions comprising terbinafine and urea
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201810192TA (en) Antibacterial compositions
SG11202000141WA (en) Powder solid dispersions comprising quercetin, process for their preparation and formulations thereof
SG11201803643TA (en) Virulence attenuated bacteria for treatment of malignant solid tumors